Quick Answer
Oric Pharmaceuticals, Inc. reported Stockholders Equity of $384.36 million for the year ending 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +58.1% in Stockholders Equity from 2024 to 2025.
- This data is from Oric Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$70.23 million | Q2 2019: -$75.95 million | Q3 2019: -$82.21 million | Q1 2020: -$98.42 million | Q2 2020: $195.25 million | Q3 2020: $184.38 million | Q1 2021: $276.08 million | Q2 2021: $258.32 million | Q3 2021: $291.54 million | Q1 2022: $253.08 million | Q2 2022: $236.87 million | Q3 2022: $214.82 million | Q1 2023: $202.81 million | Q2 2023: $268.80 million | Q3 2023: $247.41 million | Q1 2024: $328.65 million | Q2 2024: $302.40 million | Q3 2024: $273.99 million | Q1 2025: $219.74 million | Q2 2025: $324.00 million | Q3 2025: $406.92 million.
- Over the full 9 years of available data (2017 to 2025), Oric Pharmaceuticals, Inc.'s Stockholders Equity has grown by 981.3%.
- Historical annual values: Fiscal year 2025: $384.36 million | Fiscal year 2024: $243.12 million | Fiscal year 2023: $224.09 million | Fiscal year 2022: $222.35 million | Fiscal year 2021: $272.98 million | Fiscal year 2020: $289.78 million | Fiscal year 2019: -$90.08 million | Fiscal year 2018: -$64.43 million | Fiscal year 2017: -$43.61 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: